RE:RE:We shouldn't be in this positionWhat are you upset about in terms of Telesta's panel "not being prepared"?
That they didn't, at the drop of a hat, answer what day of the week the 50th patient to undergo treatment with MCNA was born on?
That they couldn't read minds and have sub-group disease free survival data for only the odd numbered CIS patients, when arranged left to right from shortest to tallest?
They brought the data they have that is meaningful, which shows positive DFS/PFS, in the standard subgroups and overall patient population, for a drug with minimal side effects, from a trial that turned out to be pretty close to what urologists and the FDA decided should be part of trial design.